Previous studies indicated that rolipram, a non-selective PDE4 inhibitor, prevented exogenous Aβ1–42 peptide-induced memory impairment, which may result from inhibition of long-form PDE4 (Zhang et al., 2014). This evidence concerns the gene PDE4A and memory impairment.